Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (September 2018)

Tuesday, November 13, 2018

Between January and September 2018, Russia imported 376.6 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 1% higher than that of the same period of 2017, and 81.1 bln RUB worth of in-bulk drugs, which is 16% higher than that of the same period of 2017. The total dynamics in monetary terms are +3.3%.

In physical terms, Russia imported 1.35 bln units of ready-made units or 24.8 bln minimum dosage units (MDU), which is 8.6% and 6% lower than that of the same period of 2017, respectively. The dynamics of the in-bulk import in physical terms is +1.2% (3.2 bln MDU.) The total dynamics is -5.3%.

The September results are not that promising. In September 2018, Russia imported 38 bln RUB worth of ready-made pharmaceutical drugs, which is 16.2% lower than that of the same period of 2017, and 9.9 bln RUB worth of in-bulk drugs, which is 47.3% higher than that of the same period of 2017. However, it is ready-made drugs that tend to be in high demand during fall.

Among the top 20 countries that import ready-made drugs to Russia, Ireland has the highest increase over the period (by 1.8 times), mostly thanks to complement inhibitor Soliris (by Alexion), which accounts for nearly 30% of the import. As for in-bulk drugs, Finland has the highest increase (by 3.3 times), while importing only Metypred and Tamoxifen (by Orion.)

The importing countries list has not seen any new names this year, and lost four of the old ones. Cuba used be the top importer, in particular in 2017 it imported 261 mln RUB worth of Heberprot-P and Ebermin (customs clearance prices).

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – September 2018)

Share: